ONC-206 is under clinical development by Chimerix and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase I drugs for High-Grade Glioma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ONC-206 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ONC-206 overview
ONC-206 is under development for the treatment of glioblastoma multiforme, high-grade glioma, Ewing sarcoma, gliosarcoma, anaplastic astrocytoma, pilocytic astrocytoma, oligodendroglioma, pheochromocytoma, triple-negative breast cancer (TNBC), hepatocellular carcinoma, small-cell lung cancer, ependymoma, medulloblastoma, primitive neuroectodermal tumor (PNET), meningioma, glioma, endometrial cancer, atypical teratoid rhabdoid tumor, ovarian cancer and cholangiocarcinoma. it is administered orally. The drug candidate is a second generation analogue of ONC-201. It acts by targeting dopamine D2 and D3 receptors and ClpP.
It was also under development for the treatment of neuroendocrine tumors.
Chimerix overview
Chimerix is a biopharmaceutical company that develops, discovers, and commercializes novel and oral antiviral therapeutics. The company’s pipeline product includes ONC201, ONC206, ONC212 and CMX521 drug candidates. Its products are used to treat various diseases like malignant glioma, neuroendocrine tumors, solid tumors, COVID-19 and IND-enabling studies. Its ONC201 is a clinical-stage development for H3 K27M-mutant diffuse glioma as its lead indication ONC206 for adult and pediatric patients with primary central nervous system tumors. The organization works in partnership with Oncoceutics, Inc., Cantex Pharmaceuticals, BARDA, and SymBio Pharmaceuticals. Chimerix is headquartered in Durham, North Carolina, the US.
For a complete picture of ONC-206’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
